Development of antimalarial drugs and their application in China: a historical review by Chang Chen
Chen Infectious Diseases of Poverty 2014, 3:9
http://www.idpjournal.com/content/3/1/9SCOPING REVIEW Open AccessDevelopment of antimalarial drugs and their
application in China: a historical review
Chang ChenAbstract
This historical review covers antimalarials developed in China, which include artemisinin, artemether, artesunate,
and dihydroartemisinin, as well as other synthetic drugs such as piperaquine, pyronaridine, benflumetol (lumefantrine),
and naphthoquine. The curative effects of these antimalarials in the treatment of falciparum malaria, including
chloroquine-resistant strain, are especially discussed. Following the World Health Organization (WHO)
recommended artemisinin-based combination therapy (ACT), different combinations of artemisinin, or its derivative,
along with another antimalarial drug were orally used to treat Plasmodium falciparum infections. The recrudescence
rates were low, gametocyte carriers lessened, and the curative rate increased remarkably. The combination therapy
effectively deferred the emergence of drug resistance in the parasite. The regulation “The guidelines and regimens
for the use of antimalarial drugs in China” was issued to guide rational application and standardize malaria treatment in
the country. As the recommended first-line drug to treat falciparum malaria in the world, ACT was adopted in the
regulation. In response to the global initiative of malaria eradication proposed by the UN Millennium Development
Goals (MDGs), the Chinese government has set a target to eliminate malaria by 2020.
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In China, malaria was not only widespread but also one
of the most threatening diseases to people’s health. His-
torically, traditional Chinese medicinal herbs were used
for thousands of years as a folk remedy to treat malaria.
Before the 1950s, the antimalarial quinine was imported
into the country in great quantities [1].
Quinine was first isolated from the cinchona bark by
European scientists in the 1920s. The trees of Cinchona
officinalis L., Rubiaceae, grew wild in South America and
were cultivated in Java, Indonesia. During the Second
World War, there was no supply of quinine because Java
was occupied by Japanese troops. Because of these cir-
cumstances, Chinese scientists tried to isolate an active
principle against malaria from the root of the plantCorrespondence: chenchang1933@126.com
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unless otherwise stated.Dichroa febrifuga L., Saxifragaceae, another traditional
herbal medicine, in the early 1940s. The principle was
named ‘β-dichroine’ or ‘febrifugine’, and its chemical
structure was identified. Two other principles with anti-
malarial activity were also isolated from the kernel of the
plant Brucea javanica (L.) M., Simarubaceae, and were
named ‘bruceine D’ and ‘bruceine E’, respectively. Their
chemical structures were also clarified. However, the in-
vestigations did not make further progress into their
clinical use [1].
In the early 1940s, chloroquine, an erythrocytic schi-
zonticide of plasmodia, was developed in Western coun-
tries. Primaquine and pyrimethamine were synthesized
in 1946 and 1951, respectively, and used for radical cure
and causal prophylaxis in malaria control.
In 1958, the abovementioned chloroquine, primaquine,
and pyrimethamine were also manufactured in China for
malaria control. The productive techniques of the drugs
were improved in order to reduce the costs to meet the
needs of large-scale malaria control [1].
Chloroquine-resistant Plasmodium falciparum was found
and spread in the early 1960s in Southeast Asia [2]. To im-
prove the research capacities for drug development, animalis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Chemical structures of artemisinins and semi-synthesized
derivatives.
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including P. berghei and the chloroquine-resistant strain of
P. berghei in mice, and P. inui in rhesus monkeys (Macaca
mulatta). Later, two more experimental models, P. cyno-
molgi and P. knowlesi in rhesus monkeys, were established.
The new antimalarials were studied and synthesized at a
few institutes in the country. Some of the new synthesized
compounds were found to have an effect against plasmodia
in the blood [1].
During the Vietnamese War in the 1960s, there was an
increase of incidence and mortality of chloroquine-
resistant falciparum malaria on the border of the Yunnan
Province. This situation inspired researchers to actively
develop alternative antimalarials that were effective to
treat chloroquine-resistant malaria.
To strengthen the research on antimalarials, an exten-
sive cooperation was organized by the Chinese govern-
ment in 1967 for drug development with participation of
relevant institutions and pharmaceutical companies. Sys-
tematic researches from chemical syntheses to pharma-
cotoxicology to clinical trials were carried out. Among
the synthetic compounds and principles extracted, a
few were clinically proven to be highly effective to
treat P. falciparum with chloroquine resistance, in-
cluding artemisinin isolated from a medicinal herb,
which, together with its derivatives, aroused a great
interest globally at a later stage.
In line with the requirement of malaria control, anti-
malarial drugs should be rationally used for achieving a
curative effect, interruption of transmission, and avoid-
ance or deferment of the development of drug resistance.
Therefore, the regulation “The guidelines and regimens
for the use of antimalarial drugs in China” was issued and
revised in 2009 [3]. Artemisinin-based combination ther-
apy (ACT), proposed by the WHO [4] as a recommended
first-line drug to treat falciparum malaria in the world,
was adopted in the regulation.
Artemisinin and its derivatives
In the late 1960s, Chinese scientists investigated active
principles against malaria from different medicinal herbs.
Various principles showed actions in malaria parasites,
and their chemical structures were also determined and
identified. Soon after, an important principle was isolated
and screened by P. berghei in mice. It was a totally new
agent: artemisinin. Its derivatives were then semi-
synthesized and proven to be active antimalarials (see
Figure 1).
Discovery of artemisinin
In 1973, an effective principle against malaria was suc-
cessfully isolated from the aerial part of the plant Arte-
misia annua L., Compositae, and named ‘artemisinin’
(see Figure 1). Interestingly, the other plants in the samegenus Artemisia did not show any activity in malaria
parasites [5]. The plants in Artemisia, all called ‘qinghao’,
were used for malaria treatment in ancient times. There-
fore, artemisinin, isolated from Artemisia annua, was
also called ‘qinghaosu’ in China.
There is a sesquiterpene lactone with a peroxy linkage
in the structure of artemisinin, which is a novel type
different from all other antimalarial drugs currently
available [6,7].
Experiments demonstrated that artemisinin was an
erythrocytic plasmodicide and not active in exoerythro-
cytic stages of plasmodia. The test in mice infected with
chloroquine-resistant P. berghei showed a low cross-
resistance to chloroquine [8,9]. In an in vivo test, artemi-
sinin could be rapidly absorbed, widely distributed, and
quickly metabolized, with a half-life of 0.5–0.7 h. The
three metabolites found in urine exhibited no action in
the parasite [10]. Artemisinin was not soluble in water
and oil, and clinically it was applied in the formulas of
tablet, water or oil suppositories, or suspension.
Artemisinin showed therapeutic action in the treat-
ment of vivax malaria, however, the curative rate was
only about 15% [9]. In the treatment of falciparum mal-
aria, it needed a large dosage, and the recrudescence rate
of the parasites was high. Therefore, the drug is not used
alone in malaria treatment but in combination with an-
other antimalarial drug.
The poor solubility and low curative rate of artemisi-
nin stimulated the researchers to transform its chemical
structure and synthesize water/oil-soluble derivatives
[11]. The effect of those derivatives was better than that
of the parent artemisinin. Among them, artemether,
artesunate, and dihydroartemisinin were developed suc-
cessively to form the novel antimalarial drugs, artemisi-
nins (see Figure 1).
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Artemisinins showed similar qualities to each other (see
Figure 1). They were effective against erythrocytic stages
of plasmodia and possessed low cross-resistance to
chloroquine in the chloroquine-resistant strain of P. ber-
ghei in mice [8,9]. The antimalarial action of artemisi-
nins occurred in the membrane structure; initial action
on the membrane of food vacuoles, mitochondria mem-
brane, etc., and autophagic vacuoles were formed to kill
parasites [8].
The experiments of subacute toxicity in animals showed
that artemisinins could dose-dependently increase brain-
stem neurotoxicity [12]; the audit sensory was easily af-
fected. The toxicity of artemether was high, medium in
dihydroartemisinin, and low in artesunate and artemisinin.
Clinically, however, the toxicity was not reported. Other
studies revealed that the toxic effect of artemisinins was
largely manifested in the haematopoietic cells of the bone
marrow, especially those of the erythroid series. In
addition, the toxic effect on the cardiac muscle and liver
was also found following the administration of artemisi-
nins into animals [13,14], but no similar clinical toxicity
was observed in humans. Studies in mice and rats indi-
cated that artemisinins showed an apparent embryotoxi-
city. Both dead fetus and absorption of fetus were
observed in gestational mice and rats. No teratogenicity
was found, but artesunate administered even with a small
dose exhibited the above fetal toxicities, with teratogenesis
of the umbilical hernia in fetus and dead fetus [15]. There-
fore, pregnant women were advised to be cautious with
artemisinins and the drugs were contraindicated to
women in their first trimester of pregnancy.
Artemether
Artemether (see Figure 1) was obtained through semi-
synthesis from artemisinin in 1976 [11]. It was still in-
soluble in water, but soluble in oil, therefore it could be
formulated as a tablet or groundnut oil injection for
application in the clinic. It was sensitive to light and
heat, and slowly decomposed which meant its content
dropped if stored for a longer time [16,17]. The elimination
half-life of the drug was 0.90 ± 0.37 h in the body [18].
The cases with vivax malaria were intramuscularly
treated by a total dosage of 640 mg of artemether. The
fever subsided and the asexual parasites were cleared in
malaria cases, but the recrudescence rate was high [19].
Generally, artemether was not used to treat vivax malaria.
The cases of falciparum malaria were intramuscularly
treated with a total dosage of 240 mg or 640 mg of arte-
mether in three or five days. The average fever subsid-
ence time was within two days and the average parasite
clearance time was within three days. The recrudescence
rate for one month was 10.5–20% [20,21]. It did not
show gametocidal activity [20]. If the total dosage was600 mg by oral ingestion in the course of five days, the
recrudescence rate of treated falciparum malaria cases
was 14% [22].
Finally, an intramuscular injection regimen with a total
dosage of 640 mg of artemether, divided into eight doses
(double doses on the first day and one dose each for the
next six days) was recommended for the treatment of
falciparum malaria [3].
Artesunate
Artesunate was developed by semi-synthesis from arte-
misinin [23] (see Figure 1). It was also poorly soluble in
water, however, sodium artesunate was soluble in water
and injectable. For clinical use, 5% sodium bicarbonate
injection was added to 60 mg of artesunate, which was
then diluted with 5% glucose to obtain a 6 ml solution
of sodium artesunate. It had to be immediately adminis-
tered by intravenous or intramuscular injection, and not
be used by intravenous drip because the solution was
unstable and soon decomposed. Its elimination half-life
in the body was 0.6–0.8 h [24].
One hundred and fifty-nine patients with falciparum
malaria received a total dosage of 400 mg of artesunate
administered by intravenous or intramuscular injection
in the course of three days. The mean fever subsidence
and parasite clearance times were 26.1 h and 28.5 h, re-
spectively. The recrudescence rate was as high as 52.4%
[19]. The total dosage was increased to 600 mg by oral
ingestion in the course of five days in the treatment of
falciparum malaria; the recrudescence rate was still high
(26.7%) [25].
One hundred and six patients with cerebral malaria re-
ceived a regimen of 420 mg of artesunate by injection
over six days. Ninety-eight patients were cured and eight
died [26].
Consequently, a total dosage increased to 480 mg by
injection over seven days (60 mg/dose; two doses on the
first day, one dose each for the next six days) was rec-
ommended in the treatment of falciparum malaria [3].
Dihydroartemisinin
The semi-synthetic dihydroartemisinin was a middle
compound in synthesis (see Figure 1) and an active me-
tabolite from artemether and artesunate in the body. It
was an erythrocytic schizonticide with an elimination
half-life of 2.6 h in the body [27].
A total dosage of 480 mg of dihydroartemisinin was
divided into eight doses by oral ingestion (two doses on
the first day and one dose each for the next six consecu-
tive days). The regimen was given to 64 patients with
falciparum malaria. The mean times of fever subsidence
and parasite clearance were two and three days, respect-
ively. The recrudescence rate was about 4% followed-up
for 30 days or 35 days. Gametocytes were still present
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to treat patients with vivax malaria. The mean times of
fever subsidence and parasite clearance were two days.
The recrudescence rate was as high as 30.6% [28]. Cur-
rently, it is not used to treat vivax malaria.
Side effects of artemisinins
Clinically, the side effects of artemisinins were similar.
In general, they were well tolerated. Some patients com-
plained of dizziness, headache, nausea, vomiting, abdom-
inal pain, diarrhea, and palpitation, etc. A few patients
had rashes which disappeared after treatment with suit-
able medicine. Some patients had reticulopenia, leuco-
penia, and increased SGPT, and urea nitrogen, sinus
bradycardia, arrhythmia or premature ventricular beat.
Usually the side effects disappeared in one to three days
or seven days after treatment.
Synthetic new antimalarial drugs
Chemical syntheses have been another important way
for developing new antimalarials. Among numerous che-
micals, four compounds (see Figure 2) showed remark-
able action in malarial parasites and were developed as
new antimalarials in the country between the 1960s and
the 1980s (see Table 1).
Piperaquine
Originally developed in France in 1963, piperaquine (see
Figure 2), identical to 13228RP, with long-effective action
against malaria, was synthesized by imitation in China in
1965. It was active in the erythrocytic stage of malarial
parasites and had a long-term effect on the suppressive
prophylaxis of malaria. The drug showed no action in
the exoerythrocytic stage of the parasites, and was
proved to have cross-resistance to chloroquine [30]. It
was retained in the body for a long time after oralFigure 2 Chemical structures of synthetic antimalarial drugs.administration with an elimination half-life of about nine
days. A large amount of the drug was stored in the liver,
kidney, and other tissues after oral use in mice, and the
release was delayed [31]. Its metabolite in the body was
not found. Its killing effect on the asexual forms was due
to the interference to the structure of food vacuoles of P.
berghei in mice [32].
Field trials of the suppressive prophylaxis were carried
out in the transmission season in Hainan. Five thousand,
seven hundred and eighty-one person-times orally re-
ceived a single dose of 600 mg of piperaquine monthly
from June to September in 1973; the monthly incidence
decreased correspondingly from 3.2% to 1.4%. The inci-
dence of the non-medicated control group with 264 per-
sons in the same residential area was 8.0% in June and
10.3% in September. With the parasite carriers as sub-
jects, 376 received the above regimen from June to
September in 1974. The rate of parasite carriers re-
duced from 33.8% before administration to 10.6% after
the last administration. Among the subjects, 57.6–59%
displayed recrudescence or illness 21–30 days after
dosing, indicating that the actual period of suppressive
prophylaxis afforded by the drug was about 20 days [33].
A total oral dosage of 1.5 g of piperaquine was given
to cases with falciparum malaria. The dosage was di-
vided into five doses (two doses the first time, one dose
after a 6 h interval, and two the next day). The mean
fever subsidence time was about two days and the mean
parasite clearance time was about three days. The recru-
descence rate was 14.9% or 18% [34,35], followed-up for
30 days. The cases with gametocytes were 74.5% after
treatment [34].
The side effects noted were headaches, dizziness, list-
lessness, somnolence, vomiting, abdominal pain, diar-
rhea, facial tingling, and reduction of reticulocytes. They
were mild and recoverable after treatment. A few cases
showed asthma, stuffiness in the chest or dyspnea, palpi-
tations, or I° A-V block, which disappeared soon after a
proper rest. A few women complained of irregular men-
struation which normalized after two months. Pipera-
quine was contraindicated to the patients with severe
acute hepatism, nephropathy, and heart disease, and
pregnant women were advised to use with caution.
In the late 1980s in China, piperaquine was used as a
prophylactic and therapeutic agent in malaria control for
10 years. The resistance rate of P. falciparum to the drug
was 72.9–96.45% [36], with a wide distribution in the en-
demic area in southern China. In 1993, 51 cases of fal-
ciparum malaria received piperaquine with the routine
treatment. Only 17 cases were sensitive to the drug and
the average time of parasite clearance was 105 ± 17 h. The
parasites in 34 cases were not cleared seven days after
treatment. Respectively, 10, 11, and 13 cases showed RI-
RIII resistance [37].
Table 1 Artemisinins and other antimalarials
Drug Date of discovery
or creation
Initial action in parasite Cross- resistance
to CQ*
Half-life (h) Route of administration
for treatment
Reference
Artemisinin 1973 Membrane system, on membrane
of food vacuoles etc.
Low 0.5–0.7 po [5,8-10]
Artemether 1976 Ditto 0.90 ± 0.37 po, im [8,11,18]
Artesunate 1977 Ditto 0.6–0.8 po, im, iv [23,24]
Dihydroartemisinin 1976 Ditto 2.6 po [11,27]
Piperaquine 1965 Food vacuoles Possession 216 po [30-32]
Pyronaridine 1970 1. Food vacuoles Without 65,251** po, im, iv drip [38-45]
2. Pellicular complexes
Benflumetol 1976 *** *** 47.4 po [51,52]
Naphthoquine 1981 Membrane system Possession 41–57 po [56]
*The tests were against P. berghei in mice. CQ: chloroquine.
**By different methods.
***The initial action and cross-resistance of the drug were reported to be similar to those of mefloquine.
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prophylaxis of vivax malaria in specific populations, i.e. mo-
bile populations such as migrant workers, personnel mak-
ing crossings at the border, travellers, etc. This drug can
accumulate in the liver, and should not be given for longer
than four consecutive months [3].
Pyronaridine
Pyronaridine (see Figure 2), a new erythrocytic schizon-
ticide, was synthesized in China in 1970. No cross-
resistance to chloroquine was found [38,39]. Series of
toxicological experiments demonstrated that the toxic-
ities of pyronaridine were less significant than those of
the chloroquine control group.
Pyronaridine exerted its lethal action primarily in both
food vacuoles and pellicular complexes of the parasites
in rodent and primate models, while chloroquine exhib-
ited its primary action in the food vacuoles only and
there was no significant action in the pellicular com-
plexes. Interestingly, the effect on the pellicular com-
plexes persisted in the chloroquine-resistant strain of P.
berghei in mice when pyronaridine was given, while the
food vacuoles showed no significant change. Chloro-
quine and mefloquine showed no significant changes in
both food vacuoles and pellicular complexes against the
resistant isolates. This observation might provide a clue
of the effectiveness of pyronaridine against chloroquine,
as well as multidrug-resistant isolates of P. falciparum
and no cross-resistance between pyronaridine and
chloroquine [40-43].
The absorption of pyronaridine was rapid and widely
distributed in the body. Its elimination half-life in humans
was 65 h [44] or 251 h [45]. The difference in the estima-
tion of the half-life might be explained by the shorter ob-
servation period used in the study of the shorter half-life
and by the difference in the detection limits of the analyt-
ical methods.Pyronaridine could dose-dependently increase the rate
of fetal resorption. It possessed embryotoxicity, which
was still lower than that of the known positive control
drug, dexon (P < 0.001). No teratogenesis was noted
[46]. Pregnant women were advised to use the drug with
caution.
The total oral dosage was 1.2 g or 1.6 g divided into
four doses (two doses on the first day at 4–6 h intervals,
one dose each for the next two days). The total dosage
by intramuscular injection or intravenous drip was
100–300 mg divided into two doses given at 4–8 h in-
tervals. The regimens of pyronaridine in the treatment
of malaria were efficient and safe. Generally, the mean
fever subsidence time of the patients infected by P. vivax
or P. falciparum, or the chloroquine-resistant strain of
P. falciparum, was one to two days and the mean para-
site clearance time was one to three days. The mean
parasite clearance time by parenteral administration
was shorter than that by oral administration, and the
parasite clearance time for vivax malaria was shorter
than that for falciparum malaria [47]. The recrudes-
cence rate of vivax and falciparum malaria was about
10%, followed-up for 28 days or a month after treatment.
Over 100 cases of cerebral malaria and other severely
complicated malaria were successfully cured with emer-
gency treatment with pyronaridine.
More than 10 pregnant patients during their mid or
late trimester were also cured with pyronaridine without
any adverse effects.
In general, pyronaridine was well tolerated by patients.
Some patients complained of discomfort in the stomach
or epigastrium, dizziness, nausea, headache, abdominal
pain, and slight diarrhea. A few patients experienced
vomiting, palpitation, and allergic skin rashes which re-
covered in two days after suitable medicine was taken.
Pyronaridine was used orally to treat falciparum or
multidrug-resistant falciparum malaria in Africa, specifically
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tients were all cured with no recrudescence. The side effects
were minor and transient [48-50].
Benflumetol (lumefantrine)
Benflumetol or lumefantrine (see Figure 2) was synthe-
sized in China in 1976 [51]. It was insoluble in water or
oils, but soluble in unsaturated fatty acids such as lino-
leic acid, and therefore formulated as pills of linoleic
acid for oral administration.
The drug was effective in the erythrocytic stage of
malaria parasites, was less toxic, absorbed slowly, and
distributed rapidly in the body. The elimination half-life
in humans was 47.4 h. The cross-resistance of benflume-
tol to chloroquine was similar to that of mefloquine
[52]. Subacute toxicity studies indicated that atrophic
degeneration of the kidney glomerulus and liver degen-
eration were observed in rats and dogs, but these changes
were reversible on withdrawal. Slight hematopoietic de-
pression and an increase of leukocytes were also observed
in rats; these changes were also reversible. Benflumetol
was not mutagenic, teratogenic, and did not affect
reproduction in rats [53].
In Hainan, a total oral dosage of 3.6 g of benflumetol di-
vided into 18 or 12 doses (three doses daily at 8 h intervals
for six or four consecutive days) was used to treat falcip-
arum malaria. The mean times of fever subsidence and
parasite clearance were three days and two days, respect-
ively, with a recrudescence rate of 11.5%, and most patients
carried gametocytes for a long time after medication [54].
A total dosage of 2.4 g of benflumetol over a four-day
course was used. The mean times of fever subsidence and
parasite clearance were 29.4 ± 24.9 h and 54.7 ± 17.4 h,
respectively. The recrudescence rate was 4.1% [55].
In Yunnan, 61 cases with falciparum malaria were
treated by an oral total dosage of 2.0 g divided into five
doses (two doses on the first day, one dose daily for the
next three days). The average times of fever subsidence
and parasite clearance were within 60 h. Two days after
treatment, four out of 61 cases showed a high fever
(39°–40.4°C) and with the rate of asexual forms being
48–261%. The four cases failed treatment. The recrudes-
cence rate was 9.8% (five out of 51 cases), followed-up
for 28 days. The occurrence rate of gametocytes was
3.9% 28 days after treatment [22]. The failed four cases
might be induced by the lower sensibility of P. falcip-
arum to the drug or by a lower dosage of the drug. The
side effects of the drug included diarrhea, abdominal
pain, vomiting, dizziness, etc., which could disappear
after a nap.
Naphthoquine
Naphthoquine (see Figure 2), synthesized in China in
1981, was effective in the erythrocytic stage of malariaparasites and showed cross-resistance to chloroquine in
the test of mice infected with P. berghei [56]. The con-
centration of naphthoquine in the red blood cells was
higher than that in the blood plasma, with an elimin-
ation half-life of 41–47 h.
In Hainan, 101 patients with falciparum malaria re-
ceived a total oral dosage of 1.0 g naphthoquine given in
dosages of 600 mg and 400 mg on the first and second
day, respectively. The average times of fever subsidence
and parasite clearance were 50.9 ± 38.8 h and 58.0 ±
21.2 h, respectively. Parasites in three patients were not
cleared seven days after treatment until day 14, 21, and
29, respectively. The recrudescence rate was low [57].
No significant side effects; uncomfortable epigastrium,
abdominal distension, and, occasionally, urine in the
blood could occur [3].
A combination therapy of artemisinins with another
antimalarial drug
The results of monitoring the sensitivity of P. falciparum
to antimalarials in the field demonstrated that the sensi-
tivity of P. falciparum to artemisinins was declining [58],
and the effect of artemisinins was likewise decreasing in
the treatment of falciparum malaria in which the resist-
ant cases possibly emerged [59-64]. In order to defer the
development of resistance to artemisinins, the WHO
strongly recommended that artemisinin-based combin-
ation therapy (ACT) is applied to treat falciparum mal-
aria. Therefore, artemisinin and its derivatives were used
in combination with another synthetic antimalarial drug
to treat falciparum malaria.
Compound tablet of artemisinin and piperaquine
(co-artemisinin)
Artemisinin (62.5 mg) and piperaquine (375 mg), in a
fixed-ratio of 1:6, was mixed to form one compound tab-
let of artemisinin and piperaquine, or co-artemisinin. A
total oral dosage of the compound tablet was four tab-
lets divided into two doses (one dose daily for two con-
secutive days) to treat falciparum malaria [3].
Compound tablet of dihydroartemisinin and piperaquine
Dihydroartemisinin (40 mg) and piperaquine phosphate
(320 mg), in a fixed-ratio of 1:8, was formulated to ob-
tain one compound tablet of dihydroartemisinin and
piperaquine. An oral total dosage was four tablets (one
tablet each at 0 h, 6–8 h, 24 h, and 32 h, respectively).
Sixty-two cases of falciparum malaria were treated in
Yunnan, with average times for fever subsidence and
parasite clearance of 34.99 ± 16.51 h and 33.14 ± 11.91 h,
respectively. The negative rate of gametocytes was 95.5%.
No recrudescence was found 28 days after follow-up [65].
Similar results with a low recrudescence rate were ob-
tained in the treatment of falciparum and drug-resistant
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areas [66-71].
Compound tablet of artemether and benflumetol
(co-artemether)
One compound tablet of artemether and benflumetol
(lumefantrine), or co-artemether, was formed by com-
bining artemether (20 mg) with benflumetol (120 mg),
in a fixed-ratio of 1:6. Synergism was shown between the
two drugs. An oral dosage was 16 tablets divided into
four doses (one dose each at 0 h, 8 h, 24 h, and 48 h, re-
spectively). One hundred and sixty-seven cases with fal-
ciparum malaria were treated in 2005. The mean fever
subsidence and parasite clearance times were 20.4 ±
8.4 h and 37.9 ± 7.9 h, respectively. The recrudescence
rate was 5.9%, followed-up for 28 days [72]. In previous
field trials in the treatment of falciparum malaria, similar
results with mild side effects and 2.1% of gametocytes
carriers were obtained [22,55]. This compound tablet
could overcome the high recrudescence rate by using
artemether alone or by slow action of benflumetol alone
in the treatment of falciparum malaria.
Compound tablet of artemisinin and naphthoquine
(co-naphthoquine)
Artemisinin (125 mg) and naphthoquine (50 mg), in a
fixed-ratio of 2.5:1, was mixed to form one compound tab-
let of artemisinin and naphthoquine, or co-naphthoquine.
A total oral dosage of eight tablets was given as a single
dose to 100 patients with falciparum malaria in Hainan.
The average fever subsidence and parasite clearance times
were 17.5 ± 12.3 h and 30.0 ± 8.8 h, respectively. The re-
crudescence rate was 3%. The adverse reactions included
headache, nausea, weakness, and loss of appetite. These
were recoverable two days after withdrawal [73]. Naph-
thoquine could cause urine in the blood; the com-
pound tablet should stop being taken immediately if
that occurs [3].
Artemisinin derivative combined with pyronaridine
A combination therapy of dihydroartemisinin (300 mg)
plus pyronaridine (800 mg) divided into four doses (two
doses on the first day at 4–6 h intervals, one dose each
for the next two days) was orally administered. The two
separate drugs were simultaneously taken. Thirty-two
patients with multidrug-resistant falciparum malaria
were treated. A double blind clinical trial was performed
with routine dosage of dihydroartemisinin or pyronari-
dine alone as control groups in Hainan in 2001. The
mean fever subsidence time of the combination therapy
group was 35.7 ± 24.7 h, and asexual forms clearance
time was 23.8 ± 10.1 h. In the group taking dihydroarte-
misinin alone, the recrudescence of parasites was found
in one case with a temperature of 39.6°C on day 21, whofailed the treatment, and in four cases P. vivax appeared
between day 21 and 28 after treatment. No recrudes-
cence was found in the group taking pyronaridine alone
and the combination group, followed-up 28 days. The
gametocyte carriers occupied 16.7% in the dihydroarte-
misinin group, 60.9% in pyronaridine group, and 20.0%
in the combination group, significantly lower than the
group of pyronaridine alone (P < 0.01). No abnormality
was found in blood, urine, and ECG examinations before
or after treatment. A few patients complained of head-
aches and dizziness, but recovered in one to two days
[74]. It was considered that the combination therapy was
the ideal medication in the treatment of multidrug-
resistant falciparum malaria [74].
The above regimen of dihydroartemisinin plus pyro-
naridine was applied in the state of Eritrea, Africa in
2000. Thirteen cases with chloroquine-resistant falcip-
arum malaria received the regimen, and similar results
were obtained. Gametocyte carriers were found in 18%
of the cases on day seven after treatment [75].
A total oral dosage of artemether or artesunate (300 mg)
or dihydroartemisinin (200 mg) plus pyronaridine (800 mg),
in a course of two days and given as two separate drugs at
the same time, was taken for the treatment of falciparum
malaria. No recrudescent rate, and the gametocytes disap-
peared on day 20 after treatment. Less adverse effects were
recorded [76,77].
The Shin Poong Pharmaceutical Co. and WHO/TDR/
PRD, as partners, have developed the pyronaridine-
artesunate project for the treatment of uncomplicated
malaria [78].
Artesunate combined with amodiaquine
An oral total dosage of artesunate (600 mg) plus amo-
diaquine (1.8 g) was divided into three doses, one each
for three consecutive days. The two separate drugs were
taken simultaneously for the treatment of P. falciparum
infections. As amodiaquine could lead to agranulocytosis
and liver damage [79], it was not used in malaria
prophylaxis, and rarely used in malaria treatment in
China. If there is an adverse reaction, this combination
therapy should be discontinued immediately [3].
Amodiaquine possessed cross-resistance to chloroquine.
In 1996, an in vitro test revealed that the resistance rate of
P. falciparum to amodiaquine was 85.3–100% [36], which
was similar to, or higher than, chloroquine in the Yunnan
Province. The combination therapy with amodiaquine
should be closely monitored if used.
Application of antimalarial drugs in the control program
In view of the malaria situation and the drug-resistance
developed in P. falciparum in the country, and based on
the experience from other countries, ACT and “The
guidelines and regimens for the use of antimalarial drugs
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the guidelines which set out how to treat and control
malaria.
For the treatment of vivax malaria, a predominant spe-
cies and still sensitive to chloroquine, an oral dosage of
1.2 g of chloroquine in a three-day course, plus a dosage
of 180 mg of primaquine in an eight-day course is rec-
ommended as routine therapy of radical cure. The dos-
age of 180 mg of primaquine in an eight-day course is
designed as an anti-relapse treatment of vivax malaria.
As for prophylaxis in specific populations, i.e. mobile
populations such as the ones mentioned previously, a
single dose of 600 mg of piperaquine orally administered
once monthly is recommended. A single dose of 300 mg
of chloroquine, once every 7–10 days, is also recom-
mended for prophylaxis.
These drugs are evidently effective and affordable for
vivax malaria control. There are large numbers of vivax
malaria cases in the country and therefore, the drugs for
treatment of vivax malaria are considered as the first-
line antimalarials in China.
Because of the persistent efforts in the past decades to
control malaria, the number of indigenous falciparum
malaria cases has considerably decreased and accounts
for about 10% of the total malaria cases, mostly evident
in the border area of Yunnan and in the forest hill area
of Hainan. At the end of 2012, the percentage decreased
to 6% [80], showing that indigenous cases of falciparum
malaria are in the minority. The drugs in the combin-
ation therapy to treat falciparum malaria, as mentioned
above, are considered as second-line antimalarials in
China, but ACT is a recommended first-line drug to
treat falciparum malaria in the world.
For the emergency treatment of cerebral or other compli-
cated, severe malaria cases, artemether, artesunate, or pyro-
naridine can be the drugs of choice, administered by
intramuscular or intravenous injections, or intravenous drip.
These drugs are considered as the third-line antimalarials.
Conclusion
Drug development is one of the most important compo-
nents in malaria control due to the critical situation of
drug resistance of P. falciparum. Chinese scientists have
made great contributions to the world by developing
new drugs, including artemisinins and a few others.
These progresses have made it possible for artemisinin-
based combination therapy (ACT) to not only effectively
cure numerous cases but also defer the emergence of re-
sistance of P. falciparum to the antimalarials.
During treatment, the results were sometimes not the
same for the same drug or the same drug combination
therapy. Besides the different fields, the different results
can be explained by the different dosages, courses of
treatment, and the numbers of cases which followed-up.Generally, artemisinins are rapidly active against plas-
modia, have a long course, and have a high recrudescence
rate. After treatment with artemisinins, the gametocyte
carriers are less significant than those with piperaquine,
benflumetol, and pyronaridine. The actions against mal-
aria parasites are slow when benflumetol and naphtho-
quine are used alone, and a large dosage of benflumetol is
needed. It has been suggested that naphthoquine should
be used in combination with a rapid active antimalarial
[57]. By using drug combination therapy to treat falcip-
arum malaria, the recrudescence rate was low, the number
of gametocyte carriers lessened, and the curative rate in-
creased remarkably. If the gametocytes still persisted after
treatment, a suitable dose of primaquine will be given to
eliminate the remaining gametocytes for interrupting the
spread of P. falciparum.
With the varying results, the suitable treatment regi-
mens for the drugs and drug combination therapies
should be provided with regulations. Therefore, the
regulation “The guidelines and regimens for the use of
antimalarial drugs in China” was issued by the health au-
thority. As a recommended first-line drug to treat falcip-
arum malaria in the world, ACT has been adopted in
the regulation. It provides the norms for drug selection
and standardized treatment of malaria cases. It is also a
valid measure to avoid or defer the development of drug
resistance of P. falciparum.
As a response to the initiative of global eradication of
malaria proposed by the UN Millennium Development
Goals, and on the basis of the great successes achieved
in malaria control in the past decades, since 2010, the
Chinese government has launched a program to elimin-
ate malaria in most regions by 2015, and in the whole
country by 2020 [81].
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